TD Cowen Reaffirms Their Buy Rating on Ionis Pharmaceuticals (IONS)
In a report released today, Yaron Werber from TD Cowen maintained a Buy rating on Ionis Pharmaceuticals (IONS – Research Report), with a price ...
Ionis to host expert panel discussion on sHTG
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today it will host a webinar on Monday, April 14th at 11:00 a.m. ET ...
Biogen’s tau targeting Alzheimer’s disease therapy gets FDA Fast Track status
Biogen ( NASDAQ: BIIB) said on Wednesday that the U.S. FDA has granted Fast Track designation to BIIB080, its antisense ...
Biogen's BIIB080 Gets FDA Fast-Track Designation in Alzheimer's Disease
Biogen on Wednesday said BIIB080 is the first tau-targeting antisense oligonucleotide therapy to enter clinical development for Alzheimer's disease and that it is currently being evaluated in a global ...
Ionis Pharmaceuticals (NASDAQ:IONS) Coverage Initiated at Redburn Atlantic
Research analysts at Redburn Atlantic began coverage on shares of Ionis Pharmaceuticals (NASDAQ:IONS – Get Free Report) in a ...
Fintel on MSN3d
Redburn Atlantic Initiates Coverage of Ionis Pharmaceuticals (IONS) with Neutral Recommendation
Fintel reports that on March 31, 2025, Redburn Atlantic initiated coverage of Ionis Pharmaceuticals (NasdaqGS:IONS) with a ...
Assessing Ionis Pharmaceuticals: Insights From 8 Financial Analysts
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $55.0, with a high ...
Ionis Pharmaceuticals initiated with a Neutral at Redburn Atlantic
Redburn Atlantic analyst Joshua Smith initiated coverage of Ionis Pharmaceuticals (IONS) with a Neutral rating and $39 price target Ionis is a ...
Fierce Pharma6d
Ionis, Arrowhead, Amarin sponsor new triglyceride group to educate physicians
Ionis Pharmaceuticals and Arrowhead Pharmaceuticals have found a common cause amid their emerging rivalry. | Ionis ...
Zacks Investment Research on MSN7d
IONS Out-Licenses ex-U.S. Rights for Rare Disease Drug Tryngolza to Sobi
Ionis Pharmaceuticals IONS signed a license agreement with Sweden-based Sobi. Per the terms, Sobi will acquire exclusive ...
Brokerages Set Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Price Target at $59.56
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS – Get Free Report) has earned an average rating of “Moderate Buy” from the twenty ...